Support teaching, research, and patient care.
Kavita Sarin, M.D./Ph.D., is an Associate Professor of Dermatology and is the Director of the Stanford Skin Cancer Genetics Program at the Stanford Cancer Institute. She has an academic interest in Precision Medicine, focused on the integration of genetic and clinical patient data to inform susceptibility, prognosis, and treatments in skin cancer and other rare dermatologic disorders. Her lab applies cutting-edge sequencing and imaging technologies to better understand skin cancer and rare immunologic skin diseases. She sees patients in medical dermatology at Portola Valley and the Stanford Cancer Institute
My research encompasses two main areas: 1) Using next-generation RNA, whole genome, and exome sequencing, we are investigating the genetic alterations involved in skin cancer progression, response to therapy, and other clinical outcomes and 2) We are developing and implementing genome-wide genetic risk prediction assessments for skin cancer into clinical use and studying the impact of this information on patient care.
Computational Drug Repurposing for All EBS Cases
The study will compare gene expression differences between blistered and non-blistered skin
from individuals with all subtypes of EB, as well as normal skin from non-EB subjects. State
of the art computational analysis will be performed to help identify new drugs that might
help all EB wound healing and reduce pain. Researchers will focus on drugs that have already
been approved for treatment of other dermatologic or non-dermatologic diseases, and therefore
be repurposed for treatment of EB. Drug development is a very expensive process taking
decades for execution. Drug repurposing on the other hand, significantly reduces the cost and
shortens the amount of time that is needed to bring effective treatments to clinical use. To
date, there is no specific treatment targeting the physiology and immunologic response in EB
patients during wound healing. Market availability of repurposed medications will provide all
EB patients rapid access to treatments, thus improving their quality of life.
View full details